NewsAsia Bringing you the latest Business News from the Science Industry By Gwyneth Astles
Agilent Identifies Socioeconomic Trends in Southeast Asia
Southeast Asia is well positioned to become a global technology hub across important industries, according to global measurement company Agilent Technologies.
Speaking in Kuala Lumpur, Malaysia, Agilent executives (pictured right) identified three socioeconomic trends driving technological growth in the region: consumer safety, in particular food safety, water quality and environmental testing; next generation communication trends such as the increasing demand for bandwidth and network security issues; the increasing demand for health-care research for the global aging population.
“With the world’s economic centre shifting to emerging economies, these global trends represent an opportunity for Asian economies,” said Soon-Chai Gooi, President of Agilent Technologies, Malaysia and Singapore. “This is especially so as governments look to diversify their economies, attract foreign investment, develop their workforces and tap into new export markets.”
Building on the company’s overarching strategy in Southeast Asia, Agilent executives provided an overview of each business group and outlined recent momentum from the region:
Rod Minett, General Manager of South Asia Pacific and Korea Field Operations, Life Sciences Group, said: “This year, we will continue to build on the talent and expertise from Agilent’s supply chain in Southeast Asia. For example, we have moved the manufacturing of automation instruments and our Liquid Chromatography/Mass Spectrometry (LC/MS) instruments to Singapore. This move is expected to meet anticipated growth in Asia and the rest of the world for measurement solutions in health-care research.”
Dr Teng Chai Hock, Vice President and General Manager of Southeast Asia Pacific and Korea Field Operations, Chemical Analysis Group, identified key growth opportunities for Agilent in areas like food safety and environmental analysis.
NSF International Opens NSF Shanghai Testing Laboratory in China
NSF International, a global not-for-profit public health and safety organisation, has opened its new NSF Shanghai Testing Laboratory in Shanghai, China, expanding its services in Asia to include testing in the areas of food equipment, dietary supplements and ingredients, and consumer products. Additionally, the facility and staff will provide on-site training in the areas of food safety, pharmaceutical, medical device and dietary supplement manufacturing.
Agilent Executives at the 3 day media event in Kuala Lumpur
Dr Teng said, “The customers we work closely with in some of these emerging countries are major producers of food and raw products to the world. As the pressure to meet stringent global standards and regulations mounts, it is critical that we offer them cutting-edge technology that keeps them at the forefront of development.”
TO FIND OUT MORE CIRCLE NO. 305 InhibOx and Cosmic Discoveries Align to
Deliver Full Service Drug Discovery Offering InhibOx Ltd and Cosmic Discoveries (the independent service arm of the Institute of Life Sciences, Hyderabad, India) have announced that they have formed a close strategic partnership to deliver a full service drug discovery service offering, incorporating expert computational, medicinal and synthetic chemistry design capabilities.
chemistry expertise spans major therapeutic areas and numerous disease-relevant targets and mechanisms.
InhibOx, the computational drug discovery specialist, is pioneering the use of cloud computing to offer rigorous, full-spectrum computer-aided drug discovery capabilities to customers around the world.
Cosmic Discoveries’ diverse medicinal and synthetic
“InhibOx is extremely proud to enter into partnership with such a prestigious research establishment, led by Professor Iqbal. Their medicinal and synthetic chemistry insights give InhibOx the scope not only to design lead libraries but to deliver samples built from innovative, well-validated chemistries,” said Professor Graham Richards, Chairman & Founder of InhibOx and former Chairman of chemistry at Oxford University. Professor Javed Iqbal, President & Founder of Cosmic
Discoveries and former distinguished research scientist and global head, discovery chemistry at Dr Reddy’s laboratory, explained, “This strategic partnership allows Cosmic Discoveries to offer design and build services based on a far more diverse set of starting propositions, derived from an innovative and wider chemistry space, tuned to our unique synthetic and medicinal chemistry capabilities.”
The two organisations, in addition to offering integrated drug discovery services, will collaborate on the design of new candidate molecules in support of an internal research projects at Cosmic Discoveries.
TO FIND OUT MORE CIRCLE NO. 306 Kinaxo Extends Collaboration with Takeda
Kinaxo Biotechnologies GmbH have announced that it has entered a second collaboration with Takeda Pharmaceutical Company Ltd Osaka, Japan. Under the agreement Kinaxo will apply its quantitative phosphoproteomics technology PhosphoScout® to assist in research of drugs under development at Takeda. This will allow Takeda to take early educated decisions on drug efficacy and safety. Financial details of the agreement were not disclosed.
PhosphoScout enables quantitative analysis of
cellular phosphoproteomes on a global scale. Since signal transmission in eukaryotic cells is mainly regulated by reversible protein phosphorylation, comprehensive analysis of phosphoproteome modulation in response to drug treatment provide valuable insights into a drug’s mode of action. Furthermore, PhosphoScout can identify differentially regulated phosphorylation sites in vivo that may serve as pharmacodynamic or drug response biomarkers in clinical trials.
PhosphoScout utilises state-of-the-art mass
spectrometry methods enabling unbiased quantification of approx. 15,000 phosphorylation sites in a single experiment. Proprietary bioinformatic software tools are applied to visualise the drug’s effects on cellular signal transduction pathway and help identify phospho-protein biomarkers.
Dr Andreas Jenne, Kinaxo’s CEO said: “We are very pleased to continue our collaboration with Takeda, a world leading healthcare company, and look forward to supporting Takeda’s efforts in developing drugs.”
TO FIND OUT MORE CIRCLE NO. 308
Send us your News stories... Please email:
gwyneth@intlabmate.com To be included in our next issue, send all your Business and Financial News stories to
gwyneth@intlabmate.com
The NSF Shanghai Testing Laboratory (full name NSF Shanghai Testing Technology Company) will complement NSF’s existing certification services in China and provide companies with a means to source safer products, raw materials and ingredients from Asia through independent, third-party testing and certification.
The NSF Shanghai Testing Laboratory will work in harmony with NSF Shanghai Co, Ltd a joint venture NSF International established with the Shanghai Audit Centre of Quality System (SAC) in 2005 and is approved by the Certification and Accreditation Administration of the People's Republic of China (CNCA). Manufacturers and suppliers in China require independent system registration and product certification in order to access international markets. NSF helps companies navigate the global marketplace and bridge Western companies with the Asia market.
“NSF International is pleased to bring its testing and technology services to China and Asia. The combination of Asia’s growing export market and the need to ensure the safety and quality of raw materials, ingredients, consumer products and food creates a greater demand for third-party testing and certification services from a reputable organisation like NSF International,” said Lori Bestervelt, PhD, NSF International Senior Vice President and Chief Technical Officer.
TO FIND OUT MORE CIRCLE NO. 307
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48
